Bypassing pre-existing antibodies extends the applicability of AAV-based retinal therapies is a research paper published in Molecular Therapy (2023). On theSindex it has a DataRank of 0.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph β no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full β never from an abstract alone.
Foundation Fighting Blindness
Grant: TA-GT-0321-0802-COLU-TRAP
National Institutes of Health
Grant: 5P30EY019007
National Institutes of Health
Grant: R01EY018213
National Institutes of Health
Grant: R01EY024698
National Institutes of Health
Grant: R01EY033770
National Institutes of Health
Grant: R24EY027285
National Institutes of Health
Grant: R24EY028758
National Institutes of Health
Grant: U01 EY030580
National Institutes of Health
Grant: U54OD020351
NEI NIH HHS
Grant: P30 EY019007
FWCI
0.00
Citation Percentile
0.1%
Fields of Study
Keywords